NEWS ROOM

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

Administrator2023-03-29view:1720

The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed ? the first clinical trial of a cancer vaccine using novel ROP technology.


Read More

돌아가기
탑버튼
홈화면아이콘